Loading clinical trials...
Loading clinical trials...
A Prospective Multi-center Study to Compare the QOL and Efficacy of Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer.
This trial is going to evaluate tumor control and quality of life in patients with prostate cancer treated with endocrine therapy with or without cryoablation.
OBJECTIVES: * To determine the tumor control in patients with prostate cancer treated with radiotherapy or cryoablation * To determine the quality of life of these patients. OUTLINE: This is a multicenter study. Patients are stratified according to Gleason score (≥ 8 vs 7 vs ≤ 6), persistent prostatic specific antigen (PSA) at allocation (\> 0.5 ng/mL vs ≤ 0.5 ng/mL), participating center. Patient are allocated to two treatment arms.
Age
18 - 80 years
Sex
MALE
Healthy Volunteers
No
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Start Date
November 1, 2015
Primary Completion Date
December 1, 2017
Completion Date
December 1, 2018
Last Updated
June 12, 2017
120
ESTIMATED participants
cryoablation
PROCEDURE
Bicalutamide
DRUG
luteinizing-hormone releasing-hormone (LHRH) agonist
DRUG
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators
NCT04550494
NCT05691465
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions